• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices

cvrx

CVRx stock drops on Q1 preliminary sales number miss

April 8, 2025 By Chris Newmarker

CVRx (NASDAQ: CVRX), developer of the implantable Barostim neuromodulation device for treating heart failure symptoms, had first-quarter sales that missed the Wall Street consensus by more than $2 million. That’s according to the preliminary Q1 results that the Minneapolis-based company released after market close yesterday. By the afternoon today, CVRX shares were down more than […]

Filed Under: Bioelectronic Medicine, Business/Financial News, Cardiovascular, Featured, Funding Roundup, Neuromodulation/Neurostimulation, Wall Street Beat Tagged With: cvrx, CVRx Inc.

CVRx stock dips on Q4 EPS miss

February 5, 2025 By Sean Whooley

CVRx (Nasdaq:CVRX) shares took a hit today on fourth-quarter results that fell short of earnings per share expectations. Shares of CVRX fell 10% to $14.63 apiece in mid-morning trading today. The Minneapolis-based maker of neuromodulation devices for treating heart failure reported losses of $10.65 million. That equals 43¢ per share on sales of $15.34 million […]

Filed Under: Business/Financial News, Cardiovascular, Implants, MassDevice Earnings Roundup, Neurological, Neuromodulation/Neurostimulation, Wall Street Beat Tagged With: cvrx, CVRx Inc.

CVRx earns Medicare win for Barostim procedure

November 4, 2024 By Sean Whooley

CVRx (Nasdaq:CVRX) announced today that the Centers for Medicare and Medicaid Services (CMS) assigned a new payment classification for its Barostim device. Barostim delivers electrical pulses to baroreceptors in the wall of the carotid artery. The pulses activate the body’s baroreflex, triggering an autonomic response to the heart. CVRx designed the therapy to restore balance […]

Filed Under: Cardiovascular, Featured, Implants, Medicare, Neurological, Neuromodulation/Neurostimulation Tagged With: cvrx, CVRx Inc.

CVRx has more positive Barostim data

September 12, 2024 By Sean Whooley

CVRx (Nasdaq:CVRX) today announced new data supporting its Barostim technology for treating heart failure. Barostim delivers electrical pulses to baroreceptors in the wall of the carotid artery. The pulses activate the body’s baroreflex, triggering an autonomic response to the heart. CVRx designed the therapy to restore balance to the autonomic nervous system, reducing the symptoms […]

Filed Under: Cardiovascular, Clinical Trials, Implants, Neuromodulation/Neurostimulation Tagged With: cvrx, CVRx Inc.

CVRx adds two new faces to its board as long-serving member departs

September 3, 2024 By Sean Whooley

CVRx (Nasdaq:CVRX) announced today that it appointed Kevin Ballinger and Mitch Hill to its board of directors, effective immediately. “We are thrilled to welcome Kevin and Mitch to our Board of Directors,” said Kevin Hykes, President and CEO of CVRx. “Their extensive experience in the medical device industry, coupled with their strong track records driving […]

Filed Under: Business/Financial News, Cardiovascular, Implants, Neurological, Neuromodulation/Neurostimulation Tagged With: cvrx, CVRx Inc., Personnel Moves

CVRx earns Medicare win for Barostim procedure

August 2, 2024 By Sean Whooley

CVRx (Nasdaq:CVRX) announced today that the Centers for Medicare and Medicaid Services (CMS) reassigned its Barostim implant procedure. CMS reassigned Barostim for the inpatient setting as part of the Fiscal Year (FY) 2025 Medicare Hospital Inpatient Prospective Payment System (IPPS) final rule. In FY 2024, CMS assigned Barostim to MS-DRGs 252, 253, 254. That had […]

Filed Under: Business/Financial News, Cardiovascular, Implants, Medicare, Neurological, Neuromodulation/Neurostimulation Tagged With: Centers for Medicare and Medicaid Services (CMS), cvrx, CVRx Inc., Reimbursement

CVRx stock is down on mixed Q2 results, unchanged guidance

July 30, 2024 By Chris Newmarker

CVRx (NASDAQ: CVRX) — developer of the implantable Barostim neuromodulation device for treating heart failure symptoms — reported mixed second-quarter results and unchanged guidance. The earnings news, released after yesterday’s market close, sent the Minneapolis-based company’s shares down more than 15% to $7.85 apiece by afternoon trading today. MassDevice’s MedTech 100 Index, which includes stocks […]

Filed Under: Business/Financial News, Cardiovascular, MassDevice Earnings Roundup, Neurological, Neuromodulation/Neurostimulation, Wall Street Beat Tagged With: cvrx, CVRx Inc.

CVRx bolsters its executive ranks with hires from Abbott, Medtronic

May 15, 2024 By Chris Newmarker

CVRx (NASDAQ: CVRX) is hiring talent from Abbott and Medtronic to bolster the adoption of its Barostim device for treating heart failure symptoms. In an email to CVRx employees shared with MassDevice, CEO Kevin Hykes repeated that the Minneapolis-based company is refining its commercial strategy. “This means increasing our capabilities and focusing on broadening therapy […]

Filed Under: Bioelectronic Medicine, Business/Financial News, Cardiovascular, Featured, Neuromodulation/Neurostimulation, News Well Tagged With: cvrx, CVRx Inc., Personnel Moves

CVRx has more data supporting long-term benefits of Barostim

April 16, 2024 By Sean Whooley

CVRx (Nasdaq:CVRX) announced the publication of post-market data highlighting long-term, sustained benefits with its Barostim device. Minneapolis-based CVRx published results from the BeAT-HF trial in the European Journal of Heart Failure. Data supported Barostim treatment in heart failure patients with reduced ejection fraction. Barostim delivers electrical pulses to baroreceptors in the wall of the carotid […]

Filed Under: Cardiovascular, Clinical Trials, Implants, Neuromodulation/Neurostimulation Tagged With: cvrx, CVRx Inc.

Augmedics CEO is taking over corner office at CVRx

January 31, 2024 By Sean Whooley

CVRx (Nasdaq:CVRX) announced today that it appointed Kevin Hykes as its new president and CEO, effective Feb. 12. Hykes already has familiarity with the Minneapolis-based neurostimulation technology developer, having joined its board in December 2022. He will continue to serve on the board, with CEO Nadim Yared set to retire from the company and resign […]

Filed Under: Business/Financial News, Featured, Implants, Neurological, Neuromodulation/Neurostimulation Tagged With: cvrx, CVRx Inc., Personnel Moves

CVRx stock dips despite Street-beating Q4

January 26, 2024 By Sean Whooley

CVRx (Nasdaq:CVRX) shares took a hit today despite fourth-quarter results that beat the consensus forecast. Shares of CVRx fell 5.2% at $27.69 apiece in mid-afternoon trading today. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — rose 0.2%. The Minneapolis-based neuromodulation technology developer posted losses of $9.2 million. […]

Filed Under: Business/Financial News, Implants, MassDevice Earnings Roundup, Neurological, Neuromodulation/Neurostimulation, Wall Street Beat Tagged With: cvrx, CVRx Inc.

  • Page 1
  • Page 2
  • Go to Next Page »

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy